<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Interdiscip Perspect Infect Dis</journal-id><journal-id journal-id-type="publisher-id">IPID</journal-id><journal-title>Interdisciplinary Perspectives on Infectious Diseases</journal-title><issn pub-type="ppub">1687-708X</issn><issn pub-type="epub">1687-7098</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19277109</article-id><article-id pub-id-type="pmc">2649424</article-id><article-id pub-id-type="doi">10.1155/2008/125081</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Emerging Insights into Antibiotic-Associated Diarrhea  and <italic>Clostridium difficile</italic> Infection through the Lens of Microbial Ecology</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Walk</surname><given-names>Seth T.</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>Vincent B.</given-names></name><xref ref-type="aff" rid="I1"><sup>1, 2</sup></xref><xref ref-type="aff" rid="I2"/></contrib></contrib-group><aff id="I1"><sup>1</sup>Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109, USA</aff><aff id="I2"><sup>2</sup>Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48109, USA</aff><author-notes><corresp id="cor1">*Seth T. Walk: <email>sethwalk@umich.edu</email></corresp><fn fn-type="other"><p>Recommended by Robert A. Britton</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>4</day><month>12</month><year>2008</year></pub-date><volume>2008</volume><elocation-id>125081</elocation-id><history><date date-type="received"><day>13</day><month>8</month><year>2008</year></date><date date-type="accepted"><day>9</day><month>10</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 S. T. Walk and V. B. Young.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Antibiotics are the main, and often only, clinical intervention for prophylactic and active treatment of bacterial infections in humans.  Perhaps it is not surprising that these drugs also shift the composition of commensal bacteria inside our bodies, especially those within the gut microbial community (microbiota).  How these dynamics ultimately affect the function of the gut microbiota, however, is not fully appreciated.  Likewise, how antibiotic induced changes facilitate the outgrowth and pathogenicity of certain bacterial strains remains largely enigmatic.  Here, we discuss the merits of a microbial ecology approach toward understanding a common side effect of antibiotic use, antibiotic-associated diarrhea (AAD), and the opportunistic bacterial infections that sometimes underlie it.  As an example, we discuss how this approach is being used to address complex disease dynamics during <italic>Clostridium difficile</italic> infection.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. INTRODUCTION</title><p>The  human colon contains the mostabundant and diverse assemblage of bacteria in the body. Symbiotic interactionswith and within this complex community are now recognized as importantpredictors of human health. Aberrant community structures are associated withcomplex diseases like obesity, irritable bowel syndrome, and immunedysfunction. Antibiotic administration can disrupt the colonic ecosystem, which,in turn, leaves patients vulnerable to gastrointestinal disease. Diarrhea is acommon manifestation of antibiotic-mediated disturbance and can result fromaltered function of the disrupted microbiota, direct effects on host tissue,and colonization by opportunistic organisms that invade the altered microbialcommunity. Here, we review the relevant microbial ecology ofantibiotic-associated diarrhea with an emphasis on bacterial community dynamicsduring <italic>C. difficile</italic> infection.</p></sec><sec sec-type="section" id="sec2"><title>2. COMMONALITIES AND ASSUMPTIONS FORGI TRACT MICROBIAL ECOLOGY</title><p>When initiating a discussion of themicrobial ecology of the gastrointestinal (GI) tract, it is important to reviewsome of the common areas and assumptions investigators used when studying thisecosystem. First, the proportion ofuncultivable bacteria in the GI tract is high (&#x0223c;60%&#x02013;80%). Initially, culture-based surveys of the gutmicrobial successfully isolated and characterized large numbers of thebacterial morphotypes (i.e., distinct cellular forms) present in human feces [<xref ref-type="bibr" rid="B20">1</xref>, <xref ref-type="bibr" rid="B41">2</xref>]. However, recent surveys based on DNA sequencing have indicated that the vastmajority of genetically distinct organisms have not been isolated by culturetechniques [<xref ref-type="bibr" rid="B51">3</xref>]. These relatively new sequence-based approaches incombination with robust bioinformatics provide the framework to explore a vastamount of genetic diversity. It is now feasible to survey nearly all of thegenetic information in a given system, and this ability has ushered ina new area of research, referred to as metagenomics [<xref ref-type="bibr" rid="B53">4</xref>]. The field is still in its infancy, and muchof the data continue to be open for interpretation. It is important to notethat the currency for GI tract microbial ecology in the metagenomic era is theabundance and distribution of targeted DNA sequences and not actual organismsor randomly sampled genomes of organisms. The amplification, cloning, andsequencing of certain loci, such as the highly conserved 16S rRNA locus, arethe tools used to study the phylogenetic signal contained in the metagenome,and this is different than classical metagenomics, where one seeks to analyze thefunctional and sequence-based diversity contained in all microbial genomes ofcommunities [<xref ref-type="bibr" rid="B53">4</xref>, <xref ref-type="bibr" rid="B54">5</xref>]. Lastly, we draw attention to an early few studies thatuse culture-based approaches, but will put these data into a metagenomiccontext.</p><p>There are measurable, statistical, and real differences(i.e., not all the detectable differences are biologically significant) betweenthe bacterial communities throughout the human body (skin, mouth, vagina, GItract, etc.). Studies have shown regional differences in microbial compositionthroughout the mammalian GI tract in both the longitudinal (i.e., stomach tosmall intestine to large intestine) and axial (i.e., mucosal associated tomucus to lumen) directions [<xref ref-type="bibr" rid="B9">6</xref>&#x02013;<xref ref-type="bibr" rid="B71">8</xref>]. For further discussion on this topic,see the recent review by Peterson et al. [<xref ref-type="bibr" rid="B48">7</xref>]. Currently, most studiescircumvent the practical and ethical problems associated with direct intestinalsampling (e.g., via colonoscopy and biopsy) by using feces as a proxy [<xref ref-type="bibr" rid="B15">9</xref>]. Many of the studies reviewed here do the same and regard the bacterialcommunity in feces as representative of the gut microbiota as a whole, with thecaveat that existing spatial community differences may result in a biasedrepresentation. For example, total anaerobe countswere found to be 100 times lower in the human cecum compared to feces [<xref ref-type="bibr" rid="B34">10</xref>].</p><p>Lastly, it is generally assumed that the abundanceand distribution of an organism (16S rRNA gene sequence) and broader taxonomicgroups of organisms (sequences grouped based on percent similarity and calledoperational taxonomic units or OTUs) are important. The abundance anddistribution of OTUs are often called community structure. As we will discuss in detail below, there areobservable patterns in the gut microbiota under certain conditions. Sometaxonomic groups are very abundant, while others are at such low abundance thatthey can only be detected using highly sensitive and specific moleculartechniques. Most studies look for community structure and try to assess theunderlying mechanisms that caused it (disease, diet, drug effect, etc.). Whilethis may at first seem logical and perhaps trivial, it is currently not wellunderstood what these patterns really mean. For example, what OTUs should beused to assess structure? At the phylum level, patterns may be clear, but atthe species level, where functional variation is driven by evolutionaryprocesses, the structure may not be statistically different from a randomassemblage (due, in part, to the lack of a universal bacterial species concept[<xref ref-type="bibr" rid="B26">11</xref>]). Currently, a challenge for microbial ecologists is to understanddynamics with respect to the functional attributes of bacterial communities andnot only through the lens of taxonomy.</p></sec><sec sec-type="section" id="sec3"><title>3. NORMAL GUT MICROBIOTA</title><p>The human colon is typicallyassociated with 10<sup>11</sup> to 10<sup>12</sup> bacterial cells per gram ofcontents, and new estimates using genetic diversity suggest that the gutecosystem holds 15000&#x02013;36000 differentspecies [<xref ref-type="bibr" rid="B15">9</xref>, <xref ref-type="bibr" rid="B16">12</xref>, <xref ref-type="bibr" rid="B65">13</xref>]. Colonization normally begins at birth, and a varietyof bacteria can be detected in infant stools within the first few days aftervaginal delivery [<xref ref-type="bibr" rid="B25">14</xref>]. Among the first gut bacteria to colonize infants were <italic>Escherichia coli</italic> and <italic>Staphylococcus aureus</italic> [<xref ref-type="bibr" rid="B32">15</xref>, <xref ref-type="bibr" rid="B43">16</xref>]. These studies usedculture-based methods to show that abundance was highest at about one weekafter birth and decreased 1&#x02013;3 orders ofmagnitude within the first year, suggesting that the abundance of earlybacterial colonizers is subsequently shifted by the growing biologic complexityof this system. Recently, nonculture-based data supported these findings andshowed that multiple shifts occur among different taxonomic groups over thefirst 200 days of life [<xref ref-type="bibr" rid="B44">17</xref>]. Also, the gamma-Proteobacteria, to which <italic>E. coli</italic> belongs, appear to be thedominant members in these infant's GI tract. It is interesting to note that <italic>E. coli</italic> was initially discovered in 1884and studied by the famous German pediatrician Theodor Escherich because of itspresence in &#x0201c;normal&#x0201d; infant microbiota and because of its beneficial effects ondigestion [<xref ref-type="bibr" rid="B56">18</xref>].</p><p>Defining normal gut microbiota ischallenging because of the compositional heterogeneity that exists betweenhosts [<xref ref-type="bibr" rid="B28">19</xref>]. Most phylotypes (suspectedspecies) are unique to the individual being sampled [<xref ref-type="bibr" rid="B51">3</xref>]. At broader taxonomiclevels, a consistent community structure is often observed, leading to theconclusion that the gut is dominated by members of a few bacterial phyla(Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria). The human gutis described as &#x0201c;exclusive&#x0201d; because there are more divisions (phyla) ofbacteria and archaea known to exist on earth than what is typically sampledfrom human subjects (currently the Silva 16S rRNA database has 115 bacterial divisionsof which only 10 have been sampled from humans) [<xref ref-type="bibr" rid="B48">7</xref>].</p><p>The bacteria in our GI tract are important forcertain aspects of human health, and there are clear mutualisms between humanand bacterial cells [<xref ref-type="bibr" rid="B12">20</xref>]. Not surprisingly, our immune system defends againstnegative symbiotic interactions based on prior exposure and also on stimulatingmechanisms like breast feeding and vaccinations (prior exposure to living cellsis not always necessary for an effective immune response). Some of the traitsthat make us human also dictate the structure of the gut community, as themicrobiota of conspecific relatives (same species of humans, primates, andnonprimates) was most similar to each other in a recent study [<xref ref-type="bibr" rid="B31">21</xref>]. There are few data that describe the community structure of the GI tract microbiota in healthy individuals and this limits our ability to formulate generalities on the normal state. However, if we are to consider the healthyhuman gut as a theoretically-based community, where a consistent structure isdefined and used to test hypotheses, then the microbiota of individuals shouldconverge upon a similar structure under similar conditions [<xref ref-type="bibr" rid="B61">22</xref>]. In theabsence of convergence, we are left to the study of stochastic events andpatterns that are best explained by random walk models, where species traits donot correlate with the abundances along environmental gradients (for more onthe theoretical issues concerning community analysis, see Tilman [<xref ref-type="bibr" rid="B61">22</xref>]).</p><p>Because of the low degree of similarity betweenindividuals, changes in the gut microbiota are typically measured by shifts instructure. For example, a cohort study of 1032 infants showed that breast-fedinfants have a consistently different bacterial composition than bottle-fedinfants [<xref ref-type="bibr" rid="B47">23</xref>]. Based on real-time PCR and OTU specific probes, formula-fed infants(<italic>n</italic> = 232) were colonized by <italic>E. coli</italic>, <italic>C. difficile</italic>, <italic>B. fragilis</italic>, and lactobacilli more often than breast-fed infants(<italic>n</italic> = 700). Similar comparative studies have shown associations between an alteredgut microbiota and a number of human diseases, including obesity [<xref ref-type="bibr" rid="B30">24</xref>], Crohn's disease [<xref ref-type="bibr" rid="B13">25</xref>], irritable bowel syndrome [<xref ref-type="bibr" rid="B45">26</xref>], and allergies [<xref ref-type="bibr" rid="B42">27</xref>]. It is clear that our understanding of the normalgut microbiota is limited and just beginning, but comparative studies like theseillustrate a novel ability to describe the microbial ecology that underliesmany complex diseases.</p></sec><sec sec-type="section" id="sec4"><title>4. ANTIBIOTICS INCREASE HOST SUSCEPTIBILITYTO PATHOGENS</title><p>One measure of ecosystem stability, in terms ofmaintaining function [<xref ref-type="bibr" rid="B24">28</xref>], is the ability to resist invasion and subsequentdominance by immigrating organisms. For the gut ecosystem, antibiotic therapyrepresents a strong perturbation that shifts the relative proportion ofcommunity members, allowing opportunists to establish [<xref ref-type="bibr" rid="B2">29</xref>&#x02013;<xref ref-type="bibr" rid="B58">32</xref>]. Antibiotic therapies exclude members of the community by eradicatingthem directly or indirectly by breaking necessary mutualistic interactions [<xref ref-type="bibr" rid="B14">33</xref>]. During such events in murine models, the community structure wasdisrupted and enteric pathogens reached high numbers [<xref ref-type="bibr" rid="B3">34</xref>, <xref ref-type="bibr" rid="B55">35</xref>]. Similar observations underlie the proposed colonization resistance orbarrier function, provided to the host by the gut microbiota [<xref ref-type="bibr" rid="B58">32</xref>, <xref ref-type="bibr" rid="B46">36</xref>, <xref ref-type="bibr" rid="B57">37</xref>], preventing the ingress of pathogens into the gut ecosystem.</p><p>Many details about the colonization resistance functionof the microbiota have yet to be tested, but it is clear that shifts in the gutmicrobial community structure are permissive to the establishment of certainpathogens. For example, <italic>Vibrio cholerae</italic> does not normally cause disease in conventional guinea pigs, but it establishedand caused severe disease after disruption of the microbiota by pretreatmentwith streptomycin [<xref ref-type="bibr" rid="B17">38</xref>]. Similarly, it has been shown that mice with aconventional gut microbiota require a much higher infective dose (10<sup>9</sup> colony forming units per mL, CFU/mL) for colonization by a gram-negativebacterium compared to antibiotic treated mice (10<sup>2</sup> CFU/mL) [<xref ref-type="bibr" rid="B63">39</xref>]. The mechanisms behind colonization resistance inhumans are topics of ongoing research, but the gut microbiota in animal modelshas been shown to (i) utilize essential nutrients before they are available toinvading bacteria (resource limitation), (ii) limit access to attachment sites(space limitation), and (iii) produce inhibitory substances [<xref ref-type="bibr" rid="B50">40</xref>].</p><p>Many factors, including drug dose, route ofadministration, absorption, and host inactivation, dictate the intensity ofantibiotic effects on the gut microbiota (see review by Sullivan et al. [<xref ref-type="bibr" rid="B58">32</xref>] for specific effects of commonly used drugs). Anumber of culture-based and nonculture-based molecular techniques have beenused to follow bacterial community dynamics in humans upon exposure toantibiotics. Often, specific groups of OTUs are singled out with specificprobes. Temporal effects of antibiotic treatment were recently shown among  members of theBacteroidetes division using culture techniques and genetic fingerprinting(rep-PCR) [<xref ref-type="bibr" rid="B23">30</xref>]. During a case-control study of subjects taking capsules of 150 mgclindamycin (orally), each individual was sampled prior to antibiotic treatmentand at set time points throughout the following 2-year posttreatment. Theoverall diversity of this division decreased upon antibiotic treatment and remainedreduced during the entire 2 years of the study. The authors also show that thedominant community members changed markedly in relative abundance during thefirst 3 weeks of the posttreatment, suggesting that these effects were notexclusive to the rest of the microbiota.</p><p>We draw attention to these dynamics here to simplypoint out that the gut microbiota changes markedly during and after normal therapeuticcourses of antibiotics and that host susceptibility to subsequent infection isincreased as a result. We now turn to specific clinical presentations thatresult from antibiotic treatment of human patients and follow with a discussionon a microbial ecology approach to these diseases.</p></sec><sec sec-type="section" id="sec5"><title>5. ANTIBIOTIC-ASSOCIATED DIARRHEAAND <italic>C. DIFFICILE</italic></title><p>Patients undergoing antibiotictreatment often develop diarrhea (antibiotic-associated diarrhea or AAD) as aside effect of therapy. Approximately, 5%&#x02013;25% of patientson antibiotic therapy develop AAD, which can range from a mild, self-limitingillness to a serious and progressive pseudomembranous colitis [<xref ref-type="bibr" rid="B4">41</xref>, <xref ref-type="bibr" rid="B8">42</xref>]. The risk of developing disease is highly variable and depends on hostfactors (age, diet, immune system function, etc.), the type and dose ofantibiotic, and the duration of treatment. In a cohort study, Beaugerie et al. found that 17.6% (46 out of 262) of adult (&#x02265;18 years old) outpatients developeddiarrhea within 14 days after the start of treatment [<xref ref-type="bibr" rid="B7">43</xref>]. Patients that remain in the hospital are similarlyaffected. According to a prospective study of hospitalized patients in Sweden,12% (294 out of 2 462) ofpatients &#x02265;12 years old developed diarrhea within 45 days after the start oftreatment [<xref ref-type="bibr" rid="B68">44</xref>]. However, certain patient populations in thehospital appear to be at an elevated risk as 60% (9 out of 15) of individuals(ages 37&#x02013;79) enrolled in acohort study of intensive care units developed diarrhea within the first weekafter of antibiotic treatment [<xref ref-type="bibr" rid="B22">45</xref>]. These data illustrate that diarrhea is a commoncomplication of antibiotic use and suggest that critically ill patients areexquisitely susceptible to AAD.</p><p>An etiologic agent is not necessaryfor AAD, as certain drugs can cause gastrointestinal dysfunction directly [<xref ref-type="bibr" rid="B8">42</xref>]. A distinction can, then, be made betweenpathogen-associated and pathogen-independent AAD in that Koch's postulates arenot met in the classical sense. For example, if the bacteria responsible forbreaking down fermentable starches in the colon are eliminated by the effect ofan antibiotic, an osmotic diarrhea may present. In this scenario, the communityand not a defined pathogen is responsible for the disease etiology. To ourknowledge, however, replicating the disease in an otherwise na&#x000ef;ve individual byestablishing the &#x0201c;pathogenic community&#x0201d; has not been shown.</p><p>A number of opportunistic pathogens can cause diseaseduring antibiotic therapy, including <italic>Salmonella</italic> spp., <italic>Clostridium perfringens</italic>, <italic>Klebsiella oxytoca</italic>, <italic>S. aureus</italic>, <italic>Candida albicans</italic>,and <italic>C. difficile</italic>. Of these, <italic>C. difficile</italic> is the most common cause ofpathogen-associated AAD (15%&#x02013;25%), the mostcommon cause of severe disease, and it causes nearly all cases of nosocomialpseudomembranous colitis [<xref ref-type="bibr" rid="B6">46</xref>]. <italic>C. difficile</italic> is an anaerobic, sporeforming bacterium that is commonly found in soil, humans, and animals [<xref ref-type="bibr" rid="B27">47</xref>]. This toxigenic gram-positive bacillus isasymptomatically carried by 1%&#x02013;3% of the humanpopulation, but is more prevalent among infants [<xref ref-type="bibr" rid="B47">23</xref>], hospitalized patients (55.4% of the hospital population in the SwedishAAD cohort study mentioned above [<xref ref-type="bibr" rid="B68">44</xref>] were positive for <italic>C. difficile</italic> toxin), older (&#x02265;60 years) patients [<xref ref-type="bibr" rid="B27">47</xref>&#x02013;<xref ref-type="bibr" rid="B36">49</xref>], and healthcare personnel that care for patients being treated withantibiotics [<xref ref-type="bibr" rid="B64">50</xref>]. This pathogen can cause disease in nonhospitalizedpatients [<xref ref-type="bibr" rid="B10">51</xref>], where the main risk factors are antibiotic therapy,proton pump inhibitors, and the use of histamine-2-receptor antagonists [<xref ref-type="bibr" rid="B19">52</xref>].</p><p>Pseudomembranous colitis in the distal colon and rectumis fatal in 6%&#x02013;30% of cases [<xref ref-type="bibr" rid="B27">47</xref>]. Disease onset occurs several days to several weeksafter initial antibiotic treatment and certain drugs, such as clindamycin,cephalosporins, fluoroquinolones, and <italic>&#x003b2;</italic>-lactams, are associated with greaterrisk of CDAD [<xref ref-type="bibr" rid="B6">46</xref>, <xref ref-type="bibr" rid="B40">53</xref>]. Oral antibiotic therapies with vancomycin, metronidazole, bacitracin,teicoplanin, and fucidin have been shown to be an effective initial treatmentsfor CDAD [<xref ref-type="bibr" rid="B39">54</xref>]. A significant number (20%&#x02013;35%) of patientsdevelop recurrent illness caused by the same or different <italic>C. difficile</italic> strains and symptoms arise several days (usually &#x0003e;4) to several weeks after the apparent success of the initial antibiotic therapy[<xref ref-type="bibr" rid="B37">55</xref>&#x02013;<xref ref-type="bibr" rid="B66">57</xref>].</p><p>CDAD has been a recognized health problem in theUnited States and many industrialized countries for more than 30 years [<xref ref-type="bibr" rid="B5">58</xref>], but the epidemiology of the disease is changing. The prevalence and severity (case fatality rate) of CDAD continue to increasein spite of numerous discoveries concerning its epidemiology, pathogenicity,and treatment [<xref ref-type="bibr" rid="B40">53</xref>, <xref ref-type="bibr" rid="B52">59</xref>]. This increasing trend is associated with the emergence and spread ofan epidemic strain referred to as NAP1/BI (North American pulsed-field type 1,ribotype 027, restriction endonuclease analysis type BI, toxinotype III) [<xref ref-type="bibr" rid="B27">47</xref>, <xref ref-type="bibr" rid="B21">60</xref>]. As a result, the average inhospital cost of CDAD patients is estimatedto be 54% more than non-CDAD patients in the United States, adding an overall$1.1 billion to national health care costs [<xref ref-type="bibr" rid="B29">61</xref>]. Length of hospital stay also increases with CDADpatients and ranges from an average of 3.6 days for the total inpatientpopulation to 16 days for surgical inpatients [<xref ref-type="bibr" rid="B70">62</xref>].</p></sec><sec sec-type="section" id="sec6"><title>6. THE MICROBIAL ECOLOGY APPROACH TOAAD AND CDAD</title><p>There are few data that assess changes in the human gut microbiota during the course of AAD. Theonly sequence-based, microbial ecology study to date followed a 39-year-oldmale throughout an amoxicillin-clavulanic acid treatment (875 and 125 mg,resp., 2 times daily for 10 days) for acute sinusitis [<xref ref-type="bibr" rid="B69">63</xref>]. The patient developed non-CDAD within 24 hours ofthe first dose and symptoms persisted until 4 days after the final dose. Stoolsamples were taken 12 hours after the first dose (day 0), 4 days into the 10-dayregime (day 4), and at 2 weeks following the final dose (day 24). A total of84, 74, and 84 randomly cloned 16S rRNA genes were sequenced from each sample,respectively.</p><p>At 4 days into theamoxicillin-clavulanic acid therapy, the gut microbiota of this individual wasmarkedly shifted. Representation of the Bacteroides group went from exclusively <italic>B. fragilis</italic> on day 0 to almost all <italic>B. distasonis</italic> on day 4. There was also adramatic outgrowth of Enterobacteriaciae (most likely <italic>E. coli</italic>). Lastly, all members of the Clostridial rRNA cluster XIVaand Bifidobacteria groups (32% of the all sequences on day 0) were lost orbelow the detection limit.</p><p>Two weeks after the last dose of antibiotic, themicrobiota appeared to be recovering to day 0 composition. The <italic>B. fragilis</italic> and Clostridial rRNA clusterXIVa groups rebounded, while <italic>B. distasonis</italic> and Enterobacteriacea groups were drastically decreased orundetected. Interestingly, members of the Clostridial rRNA cluster IV groupwere relatively unaffected by the antibiotic treatment and were sampled at roughlyeven numbers on all 3 sampling days. In contrast, members of the Bifidobacteriagroup were lost or below detection by day 4 and remained so at day 24.  These data suggest that (i) the compositionof the gut bacterial community is dramatically shifted during antibiotictherapy, (ii) that resiliency to this drug's effects is group specific, and (iii)that it may require an extended period of time for the microbiota to recover tothe prestressed composition, if at all. More data are needed to adequatelyassess the rate and extent of recovery from this and other antibiotics and toassess how variable these effects are in the human population.</p><p>The association between CDAD and perturbations of thegut microbiota is well established but poorly understood. For example, animal(hamster and mouse) and in vitro models show antagonism between conventionalmicrobiota and <italic>C. difficile</italic> population growth [<xref ref-type="bibr" rid="B67">64</xref>]. These findings help to explain the success ofbacteriotherapy for recurrent-CDAD, where the disease was resolved by rectalinstillation of donor stool [<xref ref-type="bibr" rid="B1">65</xref>, <xref ref-type="bibr" rid="B62">66</xref>]. However, the use of probiotics and synthetic mixtures of bacteria hashad limited success [<xref ref-type="bibr" rid="B49">67</xref>] and is not currently efficacious as alternativetherapies. The hope is that a better understanding of the complexity of thissystem during CDAD infection will lead to defined manipulations of patientmicrobiota that willboth preventestablishment of this pathogen and treat acute disease.</p><p>To this end, Chang et al. recently applied the sameapproach discussed above (16S rRNA gene sequencing) to 7 patients with initial(<italic>n</italic> = 3) and recurrent (<italic>n</italic> = 4) CDAD and 3 control individuals from an outpatientclinic [<xref ref-type="bibr" rid="B11">68</xref>]. Species level identity based on 97% nucleotidesimilarity was determined for 125&#x02013;184 16S rRNAgenes per individual. To gain insightinto the overall bacterial diversity of each patient's fecal microbiota,rarefaction curves were generated from these sequence data. Rarefaction is amethod of generating idealized taxonomic &#x0201c;collectors curves&#x0201d; from communitydata through data resampling [<xref ref-type="bibr" rid="B18">69</xref>]. The shape of the rarefaction curves is thenindicative of the overall complexity of the microbiota in each community,allowing comparison of the diversity of each patient's fecal microbiota.</p><p>At this level of community sampling, inferences wererestricted to the most abundant members. However, and without exception, themicrobiota from control and initial CDAD patients was more complex than themicrobiota from recurrent CDAD patients. Furthermore, the authors were able tocombine these data with those from the non-CDAD-AAD patient [<xref ref-type="bibr" rid="B69">63</xref>] to show a clear association between microbiotacomplexity and disease outcome (i.e., Controls &#x0003e; AAD &#x0003e; initial CDAD &#x0226b; recurrent CDAD). This study not only provides a support for thebarrier function against <italic>C. difficile</italic> establishment and disease, but also because the sequences represent actualorganisms, these data can be used to identify potentially useful antagonisticrelationships in the community.</p><p>The 16S rRNA clone library approach is useful tostudy interesting symbiotic associations in bacterial communities. This andother techniques may also be useful in predicting clinical outcomes based ontheir association with specific consortia of bacteria. To do so requires a novel conceptualization ofthe disease process in that one particular organism is not necessarily definedas the causative agent, butrather the entire community is involved in causing the outcome. There is littleinformation available to generate these types of risk models, but the clinicalpotential in using microbial ecological inferences to guide therapies (i.e.,tapering antibiotic treatments, probiotics, etc.) and prevention certainlywarrants further investigation.</p></sec><sec sec-type="section" id="sec7"><title>7. CONCLUSIONS AND FUTURE DIRECTION</title><p>Comparative studies that use microbial ecologytechniques to analyze temporally sampled patients and control individuals are apromising approach to complex disease research. Traditional culture-basedmethods continue to be the gold standard for disease diagnostics, but thisapproach can only detect organisms that are easy to isolate and have simplemetabolic requirements. Since the vast majority of the human gut microbiota iscurrently noncultivable, a nonculture-based approach may be more useful for thediagnosis and prediction of clinical outcomes [<xref ref-type="bibr" rid="B59">70</xref>]. Analyzing the metagenome is such an approach andcan be used to identify members of complex bacterial communities based onnucleotide variability in conserved genes [<xref ref-type="bibr" rid="B59">70</xref>, <xref ref-type="bibr" rid="B33">71</xref>]. New technologies, such as pyrosequencing, have recently becomeavailable and attain the high throughput and resolution required to makedetailed community comparisons based on more than one locus. An added benefitof these technologies is that reagents and chemistries are constantly beingre-engineered so that efficiency is maximized at lower cost.</p></sec></body><back><ref-list><ref id="B20"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holdeman</surname><given-names>LV</given-names></name><name><surname>Good</surname><given-names>IJ</given-names></name><name><surname>Moore</surname><given-names>WEC</given-names></name></person-group><article-title>Human fecal flora: variation in bacterial composition within individuals and a possible effect of emotional stress</article-title><source><italic>Applied and Environmental Microbiology</italic></source><year>1976</year><volume>31</volume><issue>3</issue><fpage>359</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">938032</pub-id></citation></ref><ref id="B41"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>WEC</given-names></name><name><surname>Holdeman</surname><given-names>LV</given-names></name></person-group><article-title>Human fecal flora: the normal flora of 20 Japanese Hawaiians</article-title><source><italic>Journal of Applied Microbiology</italic></source><year>1974</year><volume>27</volume><issue>5</issue><fpage>961</fpage><lpage>979</lpage></citation></ref><ref id="B51"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rajili&#x00107;-Stojanovi&#x00107;</surname><given-names>M</given-names></name><name><surname>Smidt</surname><given-names>H</given-names></name><name><surname>de Vos</surname><given-names>WM</given-names></name></person-group><article-title>Diversity of the human gastrointestinal tract microbiota revisited</article-title><source><italic>Environmental Microbiology</italic></source><year>2007</year><volume>9</volume><issue>9</issue><fpage>2125</fpage><lpage>2136</lpage><pub-id pub-id-type="pmid">17686012</pub-id></citation></ref><ref id="B53"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riesenfeld</surname><given-names>CS</given-names></name><name><surname>Schloss</surname><given-names>PD</given-names></name><name><surname>Handelsman</surname><given-names>J</given-names></name></person-group><article-title>Metagenomics: genomic analysis of microbial communities</article-title><source><italic>Annual Review of Genetics</italic></source><year>2004</year><volume>38</volume><fpage>525</fpage><lpage>552</lpage></citation></ref><ref id="B54"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schloss</surname><given-names>PD</given-names></name><name><surname>Handelsman</surname><given-names>J</given-names></name></person-group><article-title>Biotechnological prospects from metagenomics</article-title><source><italic>Current Opinion in Biotechnology</italic></source><year>2003</year><volume>14</volume><issue>3</issue><fpage>303</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">12849784</pub-id></citation></ref><ref id="B9"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Castillo</surname><given-names>M</given-names></name><name><surname>Skene</surname><given-names>G</given-names></name><name><surname>Roca</surname><given-names>M</given-names></name><etal/></person-group><article-title>Application of 16S rRNA gene-targetted fluorescence <italic>in situ</italic> hybridization and restriction fragment length polymorphism to study porcine microbiota along the gastrointestinal tract in response to different sources of dietary fibre</article-title><source><italic>FEMS Microbiology Ecology</italic></source><year>2007</year><volume>59</volume><issue>1</issue><fpage>138</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">17004993</pub-id></citation></ref><ref id="B48"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>DA</given-names></name><name><surname>Frank</surname><given-names>DN</given-names></name><name><surname>Pace</surname><given-names>NR</given-names></name><name><surname>Gordon</surname><given-names>JI</given-names></name></person-group><article-title> Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases</article-title><source><italic>Cell Host &#x00026; Microbe</italic></source><year>2008</year><volume>3</volume><issue>6</issue><fpage>417</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">18541218</pub-id></citation></ref><ref id="B71"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zoetendal</surname><given-names>EG</given-names></name><name><surname>von Wright</surname><given-names>A</given-names></name><name><surname>Vilpponen-Salmela</surname><given-names>T</given-names></name><name><surname>Ben-Amor</surname><given-names>K</given-names></name><name><surname>Akkermans</surname><given-names>ADL</given-names></name><name><surname>de Vos</surname><given-names>WM</given-names></name></person-group><article-title>Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces</article-title><source><italic>Applied and Environmental Microbiology</italic></source><year>2002</year><volume>68</volume><issue>7</issue><fpage>3401</fpage><lpage>3407</lpage><pub-id pub-id-type="pmid">12089021</pub-id></citation></ref><ref id="B15"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eckburg</surname><given-names>PB</given-names></name><name><surname>Bik</surname><given-names>EM</given-names></name><name><surname>Bernstein</surname><given-names>CN</given-names></name><etal/></person-group><article-title>Diversity of the human intestinal microbial flora</article-title><source><italic>Science</italic></source><year>2005</year><volume>308</volume><issue>5728</issue><fpage>1635</fpage><lpage>1638</lpage><pub-id pub-id-type="pmid">15831718</pub-id></citation></ref><ref id="B34"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marteau</surname><given-names>P</given-names></name><name><surname>Pochart</surname><given-names>P</given-names></name><name><surname>Dor&#x000e9;</surname><given-names>J</given-names></name><name><surname>B&#x000e9;ra-Maillet</surname><given-names>C</given-names></name><name><surname>Bernalier</surname><given-names>A</given-names></name><name><surname>Corthier</surname><given-names>G</given-names></name></person-group><article-title>Comparative study of bacterial groups within the human cecal and fecal microbiota</article-title><source><italic>Applied and Environmental Microbiology</italic></source><year>2001</year><volume>67</volume><issue>10</issue><fpage>4939</fpage><lpage>4942</lpage><pub-id pub-id-type="pmid">11571208</pub-id></citation></ref><ref id="B26"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Konstantinidis</surname><given-names>KT</given-names></name><name><surname>Tiedje</surname><given-names>JM</given-names></name></person-group><article-title>Prokaryotic taxonomy and phylogeny in the genomic era: advancements and challenges ahead</article-title><source><italic>Current Opinion in Microbiology</italic></source><year>2007</year><volume>10</volume><issue>5</issue><fpage>504</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">17923431</pub-id></citation></ref><ref id="B16"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>DN</given-names></name><name><surname>Pace</surname><given-names>NR</given-names></name></person-group><article-title>Gastrointestinal microbiology enters the metagenomics era</article-title><source><italic>Current Opinion in Gastroenterology</italic></source><year>2008</year><volume>24</volume><issue>1</issue><fpage>4</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">18043225</pub-id></citation></ref><ref id="B65"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whitman</surname><given-names>WB</given-names></name><name><surname>Coleman</surname><given-names>DC</given-names></name><name><surname>Wiebe</surname><given-names>WJ</given-names></name></person-group><article-title>Prokaryotes: the unseen majority</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>1998</year><volume>95</volume><issue>12</issue><fpage>6578</fpage><lpage>6583</lpage><pub-id pub-id-type="pmid">9618454</pub-id></citation></ref><ref id="B25"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>D</given-names></name><name><surname>King</surname><given-names>T</given-names></name><name><surname>Aminov</surname><given-names>R</given-names></name></person-group><article-title>Importance of microbial colonization of the gut in early life to the development of immunity</article-title><source><italic>Mutation Research</italic></source><year>2007</year><volume>622</volume><issue>1-2</issue><fpage>58</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">17612575</pub-id></citation></ref><ref id="B32"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindberg</surname><given-names>E</given-names></name><name><surname>Nowrouzian</surname><given-names>F</given-names></name><name><surname>Adlerberth</surname><given-names>I</given-names></name><name><surname>Wold</surname><given-names>AE</given-names></name></person-group><article-title>Long-time persistence of superantigen-producing Staphylococus aureus strains in the intestinal microflora of healthy infants</article-title><source><italic>Pediatric Research</italic></source><year>2000</year><volume>48</volume><issue>6</issue><fpage>741</fpage><lpage>747</lpage><pub-id pub-id-type="pmid">11102540</pub-id></citation></ref><ref id="B43"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nowrouzian</surname><given-names>F</given-names></name><name><surname>Hesselmar</surname><given-names>B</given-names></name><name><surname>Saalman</surname><given-names>R</given-names></name><etal/></person-group><article-title>						<italic>Escherichia coli</italic> in infants' intestinal microflora: colonization rate, strain turnover, and virulence gene carriage</article-title><source><italic>Pediatric Research</italic></source><year>2003</year><volume>54</volume><issue>1</issue><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">12700366</pub-id></citation></ref><ref id="B44"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>C</given-names></name><name><surname>Bik</surname><given-names>EM</given-names></name><name><surname>DiGiulio</surname><given-names>DB</given-names></name><name><surname>Relman</surname><given-names>DA</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name></person-group><article-title>Development of the human infant intestinal microbiota</article-title><source><italic>PLoS Biology</italic></source><year>2007</year><volume>5</volume><issue>7</issue><fpage>p. e177</fpage></citation></ref><ref id="B56"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shulman</surname><given-names>ST</given-names></name><name><surname>Friedmann</surname><given-names>HC</given-names></name><name><surname>Sims</surname><given-names>RH</given-names></name></person-group><article-title>Theodor Escherich: the first pediatric infectious diseases physician?</article-title><source><italic>Clinical Infectious Diseases</italic></source><year>2007</year><volume>45</volume><issue>8</issue><fpage>1025</fpage><lpage>1029</lpage><pub-id pub-id-type="pmid">17879920</pub-id></citation></ref><ref id="B28"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurokawa</surname><given-names>K</given-names></name><name><surname>Itoh</surname><given-names>T</given-names></name><name><surname>Kuwahara</surname><given-names>T</given-names></name><etal/></person-group><article-title>Comparative metagenomics revealed commonly enriched gene sets in human gut microbiomes</article-title><source><italic>DNA Research</italic></source><year>2007</year><volume>14</volume><issue>4</issue><fpage>169</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">17916580</pub-id></citation></ref><ref id="B12"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dethlefsen</surname><given-names>L</given-names></name><name><surname>McFall-Ngai</surname><given-names>M</given-names></name><name><surname>Relman</surname><given-names>DA</given-names></name></person-group><article-title>An ecological and evolutionary perspective on humang-microbe mutualism and disease</article-title><source><italic>Nature</italic></source><year>2007</year><volume>449</volume><issue>7164</issue><fpage>811</fpage><lpage>818</lpage><pub-id pub-id-type="pmid">17943117</pub-id></citation></ref><ref id="B31"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ley</surname><given-names>RE</given-names></name><name><surname>Hamady</surname><given-names>M</given-names></name><name><surname>Lozupone</surname><given-names>C</given-names></name><etal/></person-group><article-title>Evolution of mammals and their gut microbes</article-title><source><italic>Science</italic></source><year>2008</year><volume>320</volume><issue>5883</issue><fpage>1647</fpage><lpage>1651</lpage><pub-id pub-id-type="pmid">18497261</pub-id></citation></ref><ref id="B61"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tilman</surname><given-names>D</given-names></name></person-group><article-title>Niche tradeoffs, neutrality, and community structure: a stochastic theory of resource competition, invasion, and community assembly</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2004</year><volume>101</volume><issue>30</issue><fpage>10854</fpage><lpage>10861</lpage><pub-id pub-id-type="pmid">15243158</pub-id></citation></ref><ref id="B47"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Penders</surname><given-names>J</given-names></name><name><surname>Thijs</surname><given-names>C</given-names></name><name><surname>Vink</surname><given-names>C</given-names></name><etal/></person-group><article-title>Factors influencing the composition of the intestinal microbiota in early infancy</article-title><source><italic>Pediatrics</italic></source><year>2006</year><volume>118</volume><issue>2</issue><fpage>511</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">16882802</pub-id></citation></ref><ref id="B30"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ley</surname><given-names>RE</given-names></name><name><surname>B&#x000e4;ckhed</surname><given-names>F</given-names></name><name><surname>Turnbaugh</surname><given-names>P</given-names></name><name><surname>Lozupone</surname><given-names>CA</given-names></name><name><surname>Knight</surname><given-names>RD</given-names></name><name><surname>Gordon</surname><given-names>JI</given-names></name></person-group><article-title>Obesity alters gut microbial ecology</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2005</year><volume>102</volume><issue>31</issue><fpage>11070</fpage><lpage>11075</lpage><pub-id pub-id-type="pmid">16033867</pub-id></citation></ref><ref id="B13"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dicksved</surname><given-names>J</given-names></name><name><surname>Halfvarson</surname><given-names>J</given-names></name><name><surname>Rosenquist</surname><given-names>M</given-names></name><etal/></person-group><article-title>Molecular analysis of the gut microbiota of identical twins with Crohn's disease</article-title><source><italic>The ISME Journal</italic></source><year>2008</year><volume>2</volume><issue>7</issue><fpage>716</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">18401439</pub-id></citation></ref><ref id="B45"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parkes</surname><given-names>GC</given-names></name><name><surname>Brostoff</surname><given-names>J</given-names></name><name><surname>Whelan</surname><given-names>K</given-names></name><name><surname>Sanderson</surname><given-names>JD</given-names></name></person-group><article-title>Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment</article-title><source><italic>American Journal of Gastroenterology</italic></source><year>2008</year><volume>103</volume><issue>6</issue><fpage>1557</fpage><lpage>1567</lpage><pub-id pub-id-type="pmid">18513268</pub-id></citation></ref><ref id="B42"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noverr</surname><given-names>MC</given-names></name><name><surname>Huffnagle</surname><given-names>GB</given-names></name></person-group><article-title>The &#x02018;microflora hypothesis&#x02019; of allergic diseases</article-title><source><italic>Clinical and Experimental Allergy</italic></source><year>2005</year><volume>35</volume><issue>12</issue><fpage>1511</fpage><lpage>1520</lpage><pub-id pub-id-type="pmid">16393316</pub-id></citation></ref><ref id="B24"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keitt</surname><given-names>TH</given-names></name></person-group><article-title>Coherent ecological dynamics induced by large-scale disturbance</article-title><source><italic>Nature</italic></source><year>2008</year><volume>454</volume><issue>7202</issue><fpage>331</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">18633416</pub-id></citation></ref><ref id="B2"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barc</surname><given-names>MC</given-names></name><name><surname>Bourlioux</surname><given-names>F</given-names></name><name><surname>Rigottier-Gois</surname><given-names>L</given-names></name><etal/></person-group><article-title>Effect of amoxicillin-clavulanic acid on human fecal flora in a gnotobiotic mouse model assessed with fluorescence hybridization using group-specific 16S rRNA probes in combination with flow cytometry</article-title><source><italic>Antimicrobial Agents and Chemotherapy</italic></source><year>2004</year><volume>48</volume><issue>4</issue><fpage>1365</fpage><lpage>1368</lpage><pub-id pub-id-type="pmid">15047545</pub-id></citation></ref><ref id="B23"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jernberg</surname><given-names>C</given-names></name><name><surname>L&#x000f6;fmark</surname><given-names>S</given-names></name><name><surname>Edlund</surname><given-names>C</given-names></name><name><surname>Jansson</surname><given-names>JK</given-names></name></person-group><article-title>Long-term ecological impacts of antibiotic administration on the human intestinal microbiota</article-title><source><italic>The ISME Journal</italic></source><year>2007</year><volume>1</volume><issue>1</issue><fpage>56</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">18043614</pub-id></citation></ref><ref id="B38"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Membrez</surname><given-names>M</given-names></name><name><surname>Blancher</surname><given-names>F</given-names></name><name><surname>Jaquet</surname><given-names>M</given-names></name><etal/></person-group><article-title>Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice</article-title><source><italic>The FASEB Journal</italic></source><year>2008</year><volume>22</volume><issue>7</issue><fpage>2416</fpage><lpage>2426</lpage><pub-id pub-id-type="pmid">18326786</pub-id></citation></ref><ref id="B58"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>A</given-names></name><name><surname>Edlund</surname><given-names>C</given-names></name><name><surname>Nord</surname><given-names>CE</given-names></name></person-group><article-title>Effect of antimicrobial agents on the ecological balance of human microflora</article-title><source><italic>Lancet Infectious Diseases</italic></source><year>2001</year><volume>1</volume><issue>2</issue><fpage>101</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">11871461</pub-id></citation></ref><ref id="B14"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donskey</surname><given-names>CJ</given-names></name><name><surname>Hujer</surname><given-names>AM</given-names></name><name><surname>Das</surname><given-names>SM</given-names></name><name><surname>Pultz</surname><given-names>NJ</given-names></name><name><surname>Bonomo</surname><given-names>RA</given-names></name><name><surname>Rice</surname><given-names>LB</given-names></name></person-group><article-title>Use of denaturing gradient gel electrophoresis for analysis of the stool microbiota of hospitalized patients</article-title><source><italic>Journal of Microbiological Methods</italic></source><year>2003</year><volume>54</volume><issue>2</issue><fpage>249</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">12782380</pub-id></citation></ref><ref id="B3"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barman</surname><given-names>M</given-names></name><name><surname>Unold</surname><given-names>D</given-names></name><name><surname>Shifley</surname><given-names>K</given-names></name><etal/></person-group><article-title>Enteric salmonellosis disrupts the microbial ecology of the murine gastrointestinal tract</article-title><source><italic>Infection and Immunity</italic></source><year>2008</year><volume>76</volume><issue>3</issue><fpage>907</fpage><lpage>915</lpage><pub-id pub-id-type="pmid">18160481</pub-id></citation></ref><ref id="B55"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sekirov</surname><given-names>I</given-names></name><name><surname>Tam</surname><given-names>NM</given-names></name><name><surname>Jogova</surname><given-names>M</given-names></name><etal/></person-group><article-title>Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection</article-title><source><italic>Infection and Immunity</italic></source><year>2008</year><volume>76</volume><issue>10</issue><fpage>4726</fpage><lpage>4736</lpage><pub-id pub-id-type="pmid">18678663</pub-id></citation></ref><ref id="B46"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e9;dron</surname><given-names>T</given-names></name><name><surname>Sansonetti</surname><given-names>P</given-names></name></person-group><article-title>Commensals, bacterial pathogens and intestinal inflammation: an intriguing m&#x000e9;nage &#x000e0; trois</article-title><source><italic>Cell Host &#x00026; Microbe</italic></source><year>2008</year><volume>3</volume><issue>6</issue><fpage>344</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">18541210</pub-id></citation></ref><ref id="B57"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stecher</surname><given-names>B</given-names></name><name><surname>Hardt</surname><given-names>W-D</given-names></name></person-group><article-title>The role of microbiota in infectious disease</article-title><source><italic>Trends in Microbiology</italic></source><year>2008</year><volume>16</volume><issue>3</issue><fpage>107</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">18280160</pub-id></citation></ref><ref id="B17"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freter</surname><given-names>R</given-names></name></person-group><article-title>The fatal enteric cholera infection in the guinea pig, achieved by inhibition of normal enteric flora</article-title><source><italic>The Journal of Infectious Diseases</italic></source><year>1955</year><volume>97</volume><issue>1</issue><fpage>57</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">13242854</pub-id></citation></ref><ref id="B63"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der Waaij</surname><given-names>D</given-names></name></person-group><article-title>The ecology of the human intestine and its consequences for overgrowth by pathogens such as <italic>Clostridium difficile</italic></article-title><source><italic>Annual Review of Microbiology</italic></source><year>1989</year><volume>43</volume><fpage>69</fpage><lpage>87</lpage></citation></ref><ref id="B50"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pultz</surname><given-names>NJ</given-names></name><name><surname>Stiefel</surname><given-names>U</given-names></name><name><surname>Subramanyan</surname><given-names>S</given-names></name><name><surname>Helfand</surname><given-names>MS</given-names></name><name><surname>Donskey</surname><given-names>CJ</given-names></name></person-group><article-title>Mechanisms by which anaerobic microbiota inhibit the establishment in mice of intestinal colonization by vancomycin-resistant <italic>Enterococcus</italic></article-title><source><italic>The Journal of Infectious Diseases</italic></source><year>2005</year><volume>191</volume><issue>6</issue><fpage>949</fpage><lpage>956</lpage><pub-id pub-id-type="pmid">15717271</pub-id></citation></ref><ref id="B4"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartlett</surname><given-names>JG</given-names></name></person-group><article-title>Antibiotic-associated diarrhea</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2002</year><volume>346</volume><issue>5</issue><fpage>334</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">11821511</pub-id></citation></ref><ref id="B8"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beaugerie</surname><given-names>L</given-names></name><name><surname>Petit</surname><given-names>JC</given-names></name></person-group><article-title>Microbial-gut interactions in health and disease. Antibiotic-associated diarrhoea</article-title><source><italic>Best Practice &#x00026; Research Clinical Gastroenterology</italic></source><year>2004</year><volume>18</volume><issue>2</issue><fpage>337</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">15123074</pub-id></citation></ref><ref id="B7"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beaugerie</surname><given-names>L</given-names></name><name><surname>Flahault</surname><given-names>A</given-names></name><name><surname>Barbut</surname><given-names>F</given-names></name><etal/></person-group><article-title>Antibiotic-associated diarrhoea and <italic>Clostridium difficile</italic> in the community</article-title><source><italic>Alimentary Pharmacology &#x00026; Therapeutics</italic></source><year>2003</year><volume>17</volume><issue>7</issue><fpage>905</fpage><lpage>912</lpage><pub-id pub-id-type="pmid">12656693</pub-id></citation></ref><ref id="B68"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wistr&#x000f6;m</surname><given-names>J</given-names></name><name><surname>Norrby</surname><given-names>SR</given-names></name><name><surname>Myhre</surname><given-names>EB</given-names></name><etal/></person-group><article-title>Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study</article-title><source><italic>Journal of Antimicrobial Chemotherapy</italic></source><year>2001</year><volume>47</volume><issue>1</issue><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">11152430</pub-id></citation></ref><ref id="B22"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iapichino</surname><given-names>G</given-names></name><name><surname>Callegari</surname><given-names>ML</given-names></name><name><surname>Marzorati</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impact of antibiotics on the gut microbiota of critically ill patients</article-title><source><italic>Journal of Medical Microbiology</italic></source><year>2008</year><volume>57</volume><issue>8</issue><fpage>1007</fpage><lpage>1014</lpage><pub-id pub-id-type="pmid">18628503</pub-id></citation></ref><ref id="B6"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartlett</surname><given-names>JG</given-names></name><name><surname>Gerding</surname><given-names>DN</given-names></name></person-group><article-title>Clinical recognition and diagnosis of <italic>Clostridium difficile</italic> infection</article-title><source><italic>Clinical Infectious Diseases</italic></source><year>2008</year><volume>46</volume><issue>supplement 1</issue><fpage>S12</fpage><lpage>S18</lpage><pub-id pub-id-type="pmid">18177217</pub-id></citation></ref><ref id="B27"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuijper</surname><given-names>EJ</given-names></name><name><surname>Coignard</surname><given-names>B</given-names></name><name><surname>T&#x000fc;ll</surname><given-names>P</given-names></name></person-group><article-title>Emergence of <italic>Clostridium difficile</italic>-associated disease in North America and Europe</article-title><source><italic>Clinical Microbiology and Infection</italic></source><year>2006</year><volume>12</volume><issue>supplement 6</issue><fpage>2</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">16965399</pub-id></citation></ref><ref id="B35"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>LC</given-names></name><name><surname>Coignard</surname><given-names>B</given-names></name><name><surname>Dubberke</surname><given-names>E</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Horan</surname><given-names>T</given-names></name><name><surname>Kutty</surname><given-names>PK</given-names></name></person-group><article-title>Recommendations for surveillance of <italic>Clostridium difficile</italic>-associated disease</article-title><source><italic>Infection Control and Hospital Epidemiology</italic></source><year>2007</year><volume>28</volume><issue>2</issue><fpage>140</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">17265394</pub-id></citation></ref><ref id="B36"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>LC</given-names></name><name><surname>Owings</surname><given-names>M</given-names></name><name><surname>Jernigan</surname><given-names>DB</given-names></name></person-group><article-title>						<italic>Clostridium difficile</italic> infection in patients discharged from US short-stay hospitals, 1996&#x02013;2003</article-title><source><italic>Emerging Infectious Diseases</italic></source><year>2006</year><volume>12</volume><issue>3</issue><fpage>409</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">16704777</pub-id></citation></ref><ref id="B64"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weir</surname><given-names>E</given-names></name><name><surname>Flegel</surname><given-names>K</given-names></name></person-group><article-title>Protecting against <italic>Clostridium difficile</italic> illness</article-title><source><italic>Canadian Medical Association Journal</italic></source><year>2005</year><volume>172</volume><issue>9</issue><fpage>p. 1178</fpage></citation></ref><ref id="B10"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rabatsky-Ehr</surname><given-names>T</given-names></name><name><surname>Purviance</surname><given-names>K</given-names></name><name><surname>Mlynarski</surname><given-names>D</given-names></name><name><surname>Mshar</surname><given-names>P</given-names></name><name><surname>Hadler</surname><given-names>J</given-names></name><name><surname>Sosa</surname><given-names>L</given-names></name></person-group><article-title>Surveillance for community-associated <italic>Clostridium difficile</italic>&#x02014;Connecticut, 2006</article-title><source><italic>Morbidity and Mortality Weekly Report</italic></source><year>2008</year><volume>57</volume><issue>13</issue><fpage>340</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">18385641</pub-id></citation></ref><ref id="B19"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halsey</surname><given-names>J</given-names></name></person-group><article-title>Current and future treatment modalities for <italic>Clostridium difficile</italic>-associated disease</article-title><source><italic>American Journal of Health-System Pharmacy</italic></source><year>2008</year><volume>65</volume><issue>8</issue><fpage>705</fpage><lpage>715</lpage><pub-id pub-id-type="pmid">18387898</pub-id></citation></ref><ref id="B40"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Monaghan</surname><given-names>T</given-names></name><name><surname>Boswell</surname><given-names>T</given-names></name><name><surname>Mahida</surname><given-names>YR</given-names></name></person-group><article-title>Recent advances in <italic>Clostridium difficile</italic>-associated disease</article-title><source><italic>Gut</italic></source><year>2008</year><volume>57</volume><issue>6</issue><fpage>850</fpage><lpage>860</lpage><pub-id pub-id-type="pmid">18252748</pub-id></citation></ref><ref id="B39"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>MA</given-names></name></person-group><article-title>Clinical management of <italic>Clostridium difficile</italic>-associated disease</article-title><source><italic>Clinical Infectious Diseases</italic></source><year>2007</year><volume>45</volume><issue>supplement 2</issue><fpage>S122</fpage><lpage>S128</lpage><pub-id pub-id-type="pmid">17683016</pub-id></citation></ref><ref id="B37"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McFarland</surname><given-names>LV</given-names></name><name><surname>Elmer</surname><given-names>GW</given-names></name><name><surname>Surawicz</surname><given-names>CM</given-names></name></person-group><article-title>Breaking the cycle: treatment strategies for 163 cases of recurrent <italic>Clostridium difficile</italic> disease</article-title><source><italic>American Journal of Gastroenterology</italic></source><year>2002</year><volume>97</volume><issue>7</issue><fpage>1769</fpage><lpage>1775</lpage><pub-id pub-id-type="pmid">12135033</pub-id></citation></ref><ref id="B60"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tang-Feldman</surname><given-names>Y</given-names></name><name><surname>Mayo</surname><given-names>S</given-names></name><name><surname>Silva</surname><given-names>J</given-names><suffix>Jr.</suffix></name><name><surname>Cohen</surname><given-names>SH</given-names></name></person-group><article-title>Molecular analysis of <italic>Clostridium difficile</italic> strains isolated from 18 cases of recurrent <italic>Clostridium difficile</italic>-associated diarrhea</article-title><source><italic>Journal of Clinical Microbiology</italic></source><year>2003</year><volume>41</volume><issue>7</issue><fpage>3413</fpage><lpage>3414</lpage><pub-id pub-id-type="pmid">12843107</pub-id></citation></ref><ref id="B66"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilcox</surname><given-names>MH</given-names></name><name><surname>Fawley</surname><given-names>WN</given-names></name><name><surname>Settle</surname><given-names>CD</given-names></name><name><surname>Davidson</surname><given-names>A</given-names></name></person-group><article-title>Recurrence of symptoms in <italic>Clostridium difficile</italic> infection&#x02014;relapse or reinfection?</article-title><source><italic>Journal of Hospital Infection</italic></source><year>1998</year><volume>38</volume><issue>2</issue><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">9522287</pub-id></citation></ref><ref id="B5"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartlett</surname><given-names>JG</given-names></name><name><surname>Chang</surname><given-names>TW</given-names></name><name><surname>Gurwith</surname><given-names>M</given-names></name><name><surname>Gorbach</surname><given-names>SL</given-names></name><name><surname>Onderdonk</surname><given-names>AB</given-names></name></person-group><article-title>Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia</article-title><source><italic>The New England Journal of Medicine</italic></source><year>1978</year><volume>298</volume><issue>10</issue><fpage>531</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">625309</pub-id></citation></ref><ref id="B52"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ricciardi</surname><given-names>R</given-names></name><name><surname>Rothenberger</surname><given-names>DA</given-names></name><name><surname>Madoff</surname><given-names>RD</given-names></name><name><surname>Baxter</surname><given-names>NN</given-names></name></person-group><article-title>Increasing prevalence and severity of <italic>Clostridium difficile</italic> colitis in hospitalized patients in the United States</article-title><source><italic>Archives of Surgery</italic></source><year>2007</year><volume>142</volume><issue>7</issue><fpage>624</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">17638799</pub-id></citation></ref><ref id="B21"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hubert</surname><given-names>B</given-names></name><name><surname>Loo</surname><given-names>VG</given-names></name><name><surname>Bourgault</surname><given-names>A-M</given-names></name><etal/></person-group><article-title>A portrait of the geographic dissemination of the <italic>Clostridium difficile</italic> North American pulsed-field type 1 strain and the epidemiology of <italic>C. difficile</italic>-associated disease in Qu&#x000e9;bec</article-title><source><italic>Clinical Infectious Diseases</italic></source><year>2007</year><volume>44</volume><issue>2</issue><fpage>238</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">17173224</pub-id></citation></ref><ref id="B29"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kyne</surname><given-names>L</given-names></name><name><surname>Hamel</surname><given-names>MB</given-names></name><name><surname>Polavaram</surname><given-names>R</given-names></name><name><surname>Kelly</surname><given-names>CP</given-names></name></person-group><article-title>Health care costs and mortality associated with nosocomial diarrhea due to <italic>Clostridium difficile</italic></article-title><source><italic>Clinical Infectious Diseases</italic></source><year>2002</year><volume>34</volume><issue>3</issue><fpage>346</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">11774082</pub-id></citation></ref><ref id="B70"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zerey</surname><given-names>M</given-names></name><name><surname>Paton</surname><given-names>BL</given-names></name><name><surname>Lincourt</surname><given-names>AE</given-names></name><name><surname>Gersin</surname><given-names>KS</given-names></name><name><surname>Kercher</surname><given-names>KW</given-names></name><name><surname>Heniford</surname><given-names>BT</given-names></name></person-group><article-title>The burden of <italic>Clostridium difficile</italic> in surgical patients in the United States</article-title><source><italic>Surgical Infections</italic></source><year>2007</year><volume>8</volume><issue>6</issue><fpage>557</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">18171114</pub-id></citation></ref><ref id="B69"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>VB</given-names></name><name><surname>Schmidt</surname><given-names>TM</given-names></name></person-group><article-title>ntibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota</article-title><source><italic>Journal of Clinical Microbiology</italic></source><year>2004</year><volume>42</volume><issue>3</issue><fpage>1203</fpage><lpage>1206</lpage><pub-id pub-id-type="pmid">15004076</pub-id></citation></ref><ref id="B67"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>KH</given-names></name></person-group><article-title>The microecology of <italic>Clostridium difficile</italic></article-title><source><italic>Clinical Infectious Diseases</italic></source><year>1993</year><volume>16</volume><issue>supplement 4</issue><fpage>S214</fpage><lpage>S218</lpage><pub-id pub-id-type="pmid">8324122</pub-id></citation></ref><ref id="B1"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aas</surname><given-names>J</given-names></name><name><surname>Gessert</surname><given-names>CE</given-names></name><name><surname>Bakken</surname><given-names>JS</given-names></name></person-group><article-title>Recurrent <italic>Clostridium difficile</italic> colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube</article-title><source><italic>Clinical Infectious Diseases</italic></source><year>2003</year><volume>36</volume><issue>5</issue><fpage>580</fpage><lpage>585</lpage><pub-id pub-id-type="pmid">12594638</pub-id></citation></ref><ref id="B62"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tvede</surname><given-names>M</given-names></name><name><surname>Rask-Madsen</surname><given-names>J</given-names></name></person-group><article-title>Bacteriotherapy for chronic relapsing <italic>Clostridium difficile</italic> diarrhoea in six patients</article-title><source><italic>The Lancet</italic></source><year>1989</year><volume>1</volume><issue>8648</issue><fpage>1156</fpage><lpage>1160</lpage></citation></ref><ref id="B49"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pillai</surname><given-names>A</given-names></name><name><surname>Nelson</surname><given-names>RL</given-names></name></person-group><article-title>Probiotics for treatment of <italic>Clostridium difficile</italic>-associated colitis in adults</article-title><source><italic>Cochrane Database of Systematic Reviews</italic></source><year>2008</year><issue>1</issue><comment>Article ID CD004611.</comment></citation></ref><ref id="B11"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>JY</given-names></name><name><surname>Antonopoulos</surname><given-names>DA</given-names></name><name><surname>Kalra</surname><given-names>A</given-names></name><etal/></person-group><article-title>Decreased diversity of the fecal microbiome in recurrent <italic>Clostridium difficile</italic>-associated diarrhea</article-title><source><italic>The Journal of Infectious Diseases</italic></source><year>2008</year><volume>197</volume><issue>3</issue><fpage>435</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">18199029</pub-id></citation></ref><ref id="B18"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gotelli</surname><given-names>NJ</given-names></name><name><surname>Colwell</surname><given-names>RK</given-names></name></person-group><article-title>Quantifying biodiversity: procedures and pitfalls in the measurement and comparison of species richness</article-title><source><italic>Ecology Letters</italic></source><year>2001</year><volume>4</volume><issue>4</issue><fpage>379</fpage><lpage>391</lpage></citation></ref><ref id="B59"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sundquist</surname><given-names>A</given-names></name><name><surname>Bigdeli</surname><given-names>S</given-names></name><name><surname>Jalili</surname><given-names>R</given-names></name><etal/></person-group><article-title>Bacterial flora-typing with targeted, chip-based Pyrosequencing</article-title><source><italic>BMC Microbiology</italic></source><year>2007</year><volume>7, article 108</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">17233889</pub-id></citation></ref><ref id="B33"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Lozupone</surname><given-names>C</given-names></name><name><surname>Hamady</surname><given-names>M</given-names></name><name><surname>Bushman</surname><given-names>FD</given-names></name><name><surname>Knight</surname><given-names>R</given-names></name></person-group><article-title>Short pyrosequencing reads suffice for accurate microbial community analysis</article-title><source><italic>Nucleic Acids Research</italic></source><year>2007</year><volume>35</volume><issue>18</issue><fpage>p. e120</fpage></citation></ref></ref-list></back></article>